RESUMO
An assessment was carried out of clinical effectiveness of the drug phlogenzym in 74 patients with remitting, remitting-progressive, and secondary progressive course of multiple sclerosis. Phlogenzym intake for up to one to three years resulted in decline in the incidence of complications, with their degree having come to be lower, duration of remissions longer, progression of the illness slowed down. The data secured suggest to us that phlogenzym is a safe agent. It can, we believe used in a therapeutic regimen for those patients presenting with remitting and remitting-progressive types of the course of the disease.
Assuntos
Adjuvantes Imunológicos/uso terapêutico , Bromelaínas/uso terapêutico , Esclerose Múltipla/tratamento farmacológico , Rutina/análogos & derivados , Rutina/uso terapêutico , Tripsina/uso terapêutico , Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/efeitos adversos , Adolescente , Adulto , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Bromelaínas/administração & dosagem , Bromelaínas/efeitos adversos , Combinação de Medicamentos , Eletroencefalografia , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla/imunologia , Esclerose Múltipla Crônica Progressiva/tratamento farmacológico , Esclerose Múltipla Crônica Progressiva/imunologia , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Esclerose Múltipla Recidivante-Remitente/imunologia , Rutina/administração & dosagem , Rutina/efeitos adversos , Índice de Gravidade de Doença , Fatores de Tempo , Resultado do Tratamento , Tripsina/administração & dosagem , Tripsina/efeitos adversosRESUMO
Results of the examination of more than 51 patients with multiple sclerosis and 20 patients of the control group are presented in this article. It is shown that therapy with immunosuppressive medicines (metilprednisolon, dexametason and synakten-depo) is effective as treatment of patients with multiple sclerosis at the stage of exacerbation, making positive effect on the dynamics of the neurological symptoms and immunal indices. The best results were observed among the patients of II and III level of gravity with mainly remitting type of multiple sclerosis. In the comparative aspect pulse-therapy with metilprednisolon was the most effective.
Assuntos
Cosintropina/uso terapêutico , Dexametasona/uso terapêutico , Imunossupressores/uso terapêutico , Metilprednisolona/uso terapêutico , Esclerose Múltipla/tratamento farmacológico , Adulto , Cosintropina/administração & dosagem , Dexametasona/administração & dosagem , Esquema de Medicação , Feminino , Humanos , Imunossupressores/administração & dosagem , Masculino , Metilprednisolona/administração & dosagem , Pessoa de Meia-Idade , Esclerose Múltipla/imunologia , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
A total of 57 patients with multiple sclerosis (MS) who ranged from 15 to 58 years old (18 male patients, 39 female patients) were studied together with 10 essentially healthy persons (control group). Psychoemotional disorders in MS patients were described with the aid of the Minnesota Multiphasic Personality Inventory (MMPI). All MS patients revealed changes in MMPI profile of personality. There were higher T-scores on the first, second, as well as sixth, seventh, and eighth scales. During the initial stages of the illness there prevail neurosis-like symptomatology presenting as depressive-hypochondriac syndrome. The degree of the pathological process in MS makes for aggravation of disorders in the psychoemotional sphere. During the advanced stages of the malady there occur autism, attempts at isolating oneself, disruption of interpersonal connections.
